PRODUCT CODE: ET1612-49

Recombinant RUNX1+RUNX2+RUNX3 Monoclonal Antibody (ET1612-49)

  • Recombinant

Applications

  • WB

  • ICC

  • IF

  • IHC-P

  • IP

  • FC

REACTIVITY

  • Human

  • Mouse

  • Rat

Western blot analysis of RUNX1+RUNX2+RUNX3 on Jurkat cells lysates using anti-RUNX1+RUNX2+RUNX3 antibody at 1/1,000 dilution.
  • Western blot analysis of RUNX1+RUNX2+RUNX3 on Jurkat cells lysates using anti-RUNX1+RUNX2+RUNX3 antibody at 1/1,000 dilution.
  • ICC staining RUNX1+RUNX2+RUNX3 in N2A cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • ICC staining RUNX1+RUNX2+RUNX3 in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • ICC staining RUNX1+RUNX2+RUNX3 in SHG-44 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • Immunohistochemical analysis of paraffin-embedded mouse testis tissue using anti-RUNX1+RUNX2+RUNX3 antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-RUNX1+RUNX2+RUNX3 antibody. Counter stained with hematoxylin.
  • Flow cytometric analysis of Jurkat cells with RUNX1+RUNX2+RUNX3 antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody.
Western blot analysis of RUNX1+RUNX2+RUNX3 on Jurkat cells lysates using anti-RUNX1+RUNX2+RUNX3 antibody at 1/1,000 dilution.

Applications

  • WB

  • ICC

  • IF

  • IHC-P

  • IP

  • FC

REACTIVITY

  • Human

  • Mouse

  • Rat

SPECIFICATIONS

Product Type

Recombinant Rabbit monoclonal primary

Product Name

Recombinant RUNX1+RUNX2+RUNX3 Monoclonal Antibody (ET1612-49)

Immunogen

Recombinant protein

Host

Rabbit

Positive Control

Jurkat cell lysates, SHG-44, human tonsil tissue, Jurkat.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

SD0803

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 ug/ul

PURIFICATION

Protein A affinity purified.

MOLECULAR WEIGHT

49 kDa

Isotype

IgG

APPLICATION DILUTION

  • WB

  • 1:1,000-1:2,000

  • ICC/IF

  • 1:50-1:200

  • IHC-P

  • 1:50-1:200

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

PROTEIN NAME

RUNX1+RUNX2+RUNX3

SYNONYMS

Runt-related transcription factor 1; Acute myeloid leukemia 1 protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B; PEBP2-alpha B; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core-binding factor alpha B subunit; RUNX1; AML1; CBFA2; Runt-related transcription factor 2; Acute myeloid leukemia 3 protein; Core-binding factor subunit alpha-1; CBF-alpha-1; Oncogene AML-3; Osteoblast-specific transcription factor 2; OSF-2; Polyomavirus enhancer-binding protein 2 alpha A subunit; PEA2-alpha A; PEBP2-alpha A; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core-binding factor alpha A subunit; RUNX2; AML3; CBFA1; OSF2; PEBP2A; Runt-related transcription factor 3; Acute myeloid leukemia 2 protein; Core-binding factor subunit alpha-3; CBF-alpha-3; Oncogene AML-2; Polyomavirus enhancer-binding protein 2 alpha C subunit; PEA2-alpha C; PEBP2-alpha C; SL3-3 enhancer factor 1 alpha C subunit; SL3/AKV core-binding factor alpha C subunit; RUNX3; AML2; CBFA3; PEBP2A3

TISSUE SPECIFICITY

Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.

POST-TRANSLATIONAL MODIFICATION

Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with KAT6A.; Methylated.; Phosphorylated in Ser-249 Thr-273 and Ser-276 by HIPK2 when associated with CBFB and DNA. This phosphorylation promotes subsequent EP300 phosphorylation.

SUBCELLULAR LOCATION

Nucleus, Cytoplasm.

FUNCTION

The mammalian Runt-related transcription factor (RUNX) family comprises three members, RUNX1 (also designated AML-1, PEBP2αB, CBFA2), RUNX2 (also designated AML-3, PEBP2αA, CBFA1, Osf2) and RUNX3 (also designated AML-2, PEBPαC, CBFA3). RUNX family members are DNA-binding proteins that regulate the expression of genes involved in cellular differentiation and cell cycle progression. RUNX1 is involved in hematopoiesis and is frequently targeted in human leukemia by chromosomal translocations that fuse the DNA-binding domain of RUNX1 to other transcription factors and corepressor molecules. In addition to its role in leukemogenesis, RUNX1 is also involved in sensory neuron diversification. RUNX1 promotes axonal growth, is selectively expressed in neural crest-derived TrkA+ sensory neurons and mediates TrkA transactivation in migratory neural crest cells. RUNX2 is essential for skeletal mineralization in that it stimulates osteoblast differentiation of mesenchymal stem cells, promotes chondrocyte hypertrophy and contributes to endothelial cell migration and vascular invasion of developing bones. Regulating RUNX2 expression may be a useful therapeutic tool for promoting bone formation. Mutations in the C-terminus of RUNX2 are associated with cleidocranial dysplasia syndrome, an autosomal-dominant skeletal dysplasia syndrome that is characterized by widely patent calvarial sutures, clavicular hypoplasia, supernumerary teeth, and short stature. RUNX3 is expressed in cells of hematopoietic origin, including myeloid and B-cell lines and spleen. By playing a role in controlling the growth and differentiation of gastric epithelial cells, RUNX3 is a strong candidate as a gastric cancer tumor suppressor. Specifically, hypermethylation inactivates the gene encoding RUNX3. The detection of hypermethylation at multiple regions within the RUNX3 CpG island may aid in the diagnosis and risk assessment of gastric cancer.